niftify.in

Business Line

Lupin, Takeda in pact to market gastric drug in India; stock slips.

Lupin to market Takeda’s Vonoprazan tablets in India under brand name Lupivon

Business Standard

Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India

Lupin announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialize Vonoprazan Tablets in the Indian market.

The Economic Times

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India. The drug, approved for various gastrointestinal conditions, will be marketed as Lupivon in 10 mg and 20 mg strengths. This agreement aims to enhance Lupin's gastroenterology portfolio and address unmet patient needs.

The Economic Times

Lupin shares down 1.87% as Nifty drops

A total of 22,525 shares changed hands on the counter till 01:33PM (IST).

The Economic Times

Lupin shares up 1.02% as Nifty gains

A total of 5,804 shares changed hands on the counter till time (IST).

The Economic Times

Share price of Lupin jumps as Sensex drops 25.13 points

A total of 5,571 shares changed hands on the counter till 12:22PM (IST)

The Economic Times

Share price of Lupin rises as Nifty weakens

A total of 3,668 shares changed hands on the counter till 11:46AM (IST).

The Economic Times

Sunsure Energy to supply 21 MW solar power to Lupin's Tarapur facility

Sunsure Energy has signed an agreement to supply 21MW solar power to Lupin's Tarapur facility from its 100 MW solar plant in Solapur. This deal is part of Lupin's efforts to increase renewable energy usage. Sunsure is also developing 500 MW of solar and wind energy parks in Maharashtra.

The Economic Times

Share price of Lupin falls as Sensex gains 301.64 points

A total of 140,874 shares changed hands on the counter till 01:39PM (IST)

Mint

Stocks to buy: InCred Equities adds Bajaj Finance, Hero MotoCorp, TCS to its high-conviction stock ideas for September

InCred Equities has added TCS, Bajaj Finance, Lupin, and Hero MotoCorp to its high-conviction stock list for September 2024, while removing Ajanta Pharma and others. The brokerage maintains a positive outlook for the Nifty 50, targeting 26,736, driven by favorable macroeconomic conditions.

Business Standard

Lupin shares hit 52-week high: Here's what is fueling the pharma stock

Lupin shares have yielded a return of 74.72 per cent year-to-date, while the Sensex, on the other hand, has advanced 13.72 per cent in 2024

The Economic Times

Shares of Lupin rise as Nifty drops

On the technical charts, the 200-day moving average of the stock stood at Rs 1617.89.

Mint

Lupin share price hits 52-week high on launch of overactive bladder drug in US

Lupin share price rose over 1% to a 52-week high after the FDA approved its generic Mirabegron tablets for overactive bladder, projected to generate $1.6 billion in annual US sales. Lupin and Zydus will have six months of exclusivity amid ongoing litigation.

The Economic Times

Dr Reddy's, Lupin recall products in US due to manufacturing issues

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, according to the USFDA. Dr Reddy's is recalling Ibuprofen tablets for failing impurity specifications, while Lupin is recalling Cefixime for Oral Suspension due to subpotency. Both recalls are classified as Class II, indicating potential temporary or medically reversible adverse health consequences.

The Economic Times

Share price of Lupin falls as Nifty strengthens

A total of 9,229 shares changed hands on the counter till 11:57AM (IST).

The Economic Times

Lupin launches generic cancer drug in US

Lupin has launched a generic cancer treatment drug, Doxorubicin Hydrochloride Liposome Injection, in the US market. The product is a generic version of Baxter Healthcare Corporation's Doxil and is used to treat ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma. The drug had an estimated annual sales of USD 40.9 million.

The Economic Times

Lupin shares up 0.37% as Nifty gains

The stock quoted a 52-week high price of Rs 2130.85 and low of Rs 1066.05.

The Economic Times

Share price of Lupin falls as Nifty strengthens

A total of 16,917 shares changed hands on the counter till 01:45PM (IST).

Mint

5 stocks and key lessons learnt from the Big Bull - Rakesh Jhunjhunwala

Rakesh Jhunjhunwala's legacy in the Indian stock market highlights his unique blend of vision, patience, thorough research, and calculated risks. On his second death anniversary, key lessons from his investments in Titan, Lupin, CRISIL, Viceroy Hotels, and Aptech are being remembered.

Mint

Torrent, Glenmark, Alkem, Mankind, Lupin among key drivers of Indian pharma market growth during July

Stock Market Today: Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mankind, Lupin, Alkem Laboratories were among key drivers of pharma market growth during July. Indian pharma market growth remained tepid at 6.1% suggest reports

Mint

Voltas, India Glycols & others hit 52 week high today ; Do you own any?

Following shares hit their 52 week high today - Voltas, India Glycols, Aia Engineering, Trent, Lupin

The Economic Times

Canara Bank, Lupin among 5 stocks with long buildup

undefined

Business Line

Lupin expects to up its research spends over the next two quarters

Investments in R&D touched ₹1,800 crore for fiscal 2025

Business Line

Stocks that will see action today: August 6, 2024

Buzzing stocks: MTNL, Lupin, RITES, Hudco, Sandhar Tech, Power Mech Projects, New India Assurance, VA Tech Wabag

Business Line

Stocks that will see action today: July 16

Buzzing stocks: South Indian Bank, Kokuyo Camlin,  HUL, NLC India, Tata Steel, Zee Entertainment, Aster DM, Lupin, Max Estates

The Economic Times

Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn

Lupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis, is the key product involved. The deal includes potential payments up to USD 84 million based on future milestones.

The Economic Times

Lupin stock price up 0.46 per cent as Sensex climbs

As of 30-Jun-2024, promoters held 46.7 per cent stake in the company, while FIIs held 19.32 per cent and domestic institutional investors had 16.23 per cent.

The Economic Times

Indian pharma companies faked generic viagra data to gain approval, finds US FDA

FDA's June 18 alert revealed falsified data by Synapse Labs affecting generics like Umedica's Viagra. Europe had earlier warned. Insurers might change coverage. Both Massoud Motamed and Erin Fox highlight ingredient risks. Due to confidentiality, FDA hasn't disclosed all affected drugs, suspended sales, or done significant public outreach. Identified generics include Lupin's Lipitor and Aurobindo's risendronate.

Business Standard

Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook

Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts

Business Standard

Stocks to buy and sell on July 4: Bhel, Lupin, Firstsource Solutions

Pharma index has rebounded from the key support zone and LUPIN is offering fresh buying opportunity with favorable risk to reward

The Economic Times

Lupin, Eugia recall products from US market: USFDA

Drugmakers Lupin and Aurobindo Pharma are recalling products from the American market due to manufacturing issues, as reported by the US Food and Drug Administration (USFDA). Lupin Pharmaceuticals Inc, a US-based unit of Lupin, is specifically recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) because of "failed content uniformity specifications."

The Economic Times

Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiary

Lupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development and Manufacturing Organization (CDMO) business. Abdelaziz Toumi (Abdel), with extensive experience in biotech, pharma, and CDMO sectors across multiple continents, has been appointed as the CEO of LMS.

The Economic Times

Lupin appoints Abdelaziz Toumi as CEO of newly formed arm

Lupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech, pharma, and CDMO sectors, has held roles at Bayer, Merck, and Lonza. Based in Switzerland, he will also focus on India. LMS specializes in APIs and CDMO services.